Both in Pharmaceuticals
CytomX Therapeutics vs Phathom Pharmaceuticals
Over the past year CTMX returned −14.9% and PHAT returned −35.0%; their daily moves had a correlation of 0.12.
CTMX −14.9% PHAT −35.0%Growth of $1, one year, split-adjusted
| Metric | CTMX | PHAT |
|---|---|---|
| Price | $2.75 | $7.36 |
| Market cap | $599.2M | $595.4M |
| Today | +2.23% | +0.14% |
| 1 month | −14.3% | −19.8% |
| 6 months | −37.6% | −30.1% |
| Year to date | −35.4% | −55.6% |
| 1 year | −5.2% | −37.5% |
| Revenue growth (YoY) | −92.4% | +88.0% |
| Gross margin | 100.0% | 79.7% |
| Net margin | −1457.4% | −23.7% |
| P/E (TTM) | — | — |
| Price / sales | 32.7× | 2.5× |
| Net cash | $330.3M | $16.5M |
| Dividend yield | — | — |
| Volatility (60d) | 60.5% | 80.9% |
| Short % of float | 19.3% | 18.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).